Search for: "Sanofi GmbH" Results 1 - 20 of 72
Sort by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
2 Aug 2023, 11:05 am by Sofya Asatryan
Sanofi further argued that the Board improperly shifted the burden of persuasion from Mylan to prove that the challenged claims were unpatentable to Sanofi to defend the claims of the ’614 patent as patentable. [read post]
11 Nov 2022, 9:40 am by Holman
Sanofi, marking the first time that the Court has taken up patent law’s enablement requirement since enactment of the Patent Act of 1952. [read post]
26 Sep 2022, 4:49 am by Dennis Crouch
Written Description for an Effective Treatment in Biogen International GmbH v. [read post]
29 Dec 2021, 4:16 pm by Lawrence B. Ebert
The outcome For the foregoing reasons, we affirm the four final written decisions that determined unpatentability based on Steenfeldt-Jensen: IPR2018-01670, IPR2018-01676, IPR2018-01678, and IPR2019-00979. [read post]
5 Oct 2020, 10:25 am by Dennis Crouch
., No. 19-1452; Sanofi-Aventis Deutschland GmbH v. [read post]
5 Oct 2020, 2:00 am by Annsley Merelle Ward
Standard Verlags GmbH, the Judge started by recalling that the "close connection" criteria requires the same situation of fact and law. [read post]
27 Sep 2020, 6:36 pm by Dennis Crouch
., No. 19-1452; Sanofi-Aventis Deutschland GmbH v. [read post]